कंपनी का अवलोकन
Caribou Biosciences, Inc. (CRBU) operates as a clinical-stage biopharmaceutical entity focused on clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing technologies. The company functions within the healthcare sector, specifically the biotechnology industry, where it leverages a novel CRISPR hybrid RNA-DNA platform to facilitate precise genome editing for therapeutic applications. As of the latest reporting period, the firm maintains a market capitalization of $189.41M, generates annual revenue of $11.16M, and employs a workforce of 97 individuals. These valuation and revenue figures indicate that the company is a mid-sized entity within the biotechnology landscape, operating with a significant market cap relative to its current revenue stream, which is typical for clinical-stage firms investing heavily in research and development before achieving commercial profitability.
वित्तीय स्वास्थ्य
The company reported a revenue of $11.16M over the trailing twelve months, yet recorded a net income of -$148,124,992 and an EBITDA of -$130,273,000. The substantial disparity between the $11.16M in revenue and the -$148,124,992 in net income reveals a cost structure characterized by extreme operating expenses that far exceed income generation, a common trait in early-stage biotechnology development. Free cash flow stands at -$69,796,752, indicating that the company is currently burning cash rather than generating liquidity, which limits its immediate financial flexibility and reliance on external capital sources. All three margin metrics reflect this intense expenditure phase: gross margin is 0.0%, operating margin is -722.0%, and profit margin is 0.0%, signaling that costs at every stage of production and operation currently outweigh gross sales revenue. On the balance sheet, the company holds $139.34M in cash against $27.23M in debt, supported by a debt-to-equity ratio of 22.29, which suggests a leveraged position where equity is low relative to debt obligations despite the high absolute cash balance. The current ratio of 5.71 indicates strong short-term liquidity, as the company possesses more than five times the current assets necessary to cover its current liabilities. Furthermore, the return on equity is -79.0% and return on assets is -34.3%, metrics that reveal management is currently destroying shareholder value through high burn rates rather than generating returns on the capital deployed.
मूल्यांकन आकलन
Valuation metrics for Caribou Biosciences present a complex picture due to the lack of profitability; the P/E ratio (TTM) is N/A, while the forward P/E is -1.31, implying that the market expects earnings to remain negative or for the company to reach profitability in the future. The price-to-book ratio stands at 1.53, indicating that the stock trades at a 53% premium over its book value, which may reflect investor expectations of future asset appreciation or intangible value not captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 16.97 and an EV/EBITDA of -0.59 suggest that the market is pricing the company based on revenue multiple rather than earnings, as negative EV/EBITDA confirms the absence of earnings power. Regarding trading ranges, the stock has seen a 52-week high of $3.54 and a 52-week low of $0.71; without a specific current price provided in the facts, the valuation context relies on these historical extremes to define the volatility envelope of the asset. The beta value of 2.46 indicates that the stock is significantly more volatile than the broader market, moving with high intensity relative to general market fluctuations.
Growth & Income
Revenue growth for the trailing twelve months is 89.7%, while earnings growth is N/A, illustrating a scenario where top-line expansion is occurring without corresponding bottom-line profitability, which is expected for clinical-stage firms but highlights the challenge of converting revenue into earnings. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available resources and cash reserves into research, development, and operational scaling rather than returning capital to shareholders. This non-dividend profile aligns with the company's stage of development, where capital expenditure is prioritized over income distribution to advance its genome-editing pipeline. The overall growth and income profile is defined by rapid revenue expansion coupled with significant cash consumption and zero income generation, creating a high-risk, high-reward dynamic typical of the biotechnology sector.